CIK 0001599298 · Large accelerated filer
Summit Therapeutics Inc.
Sign in to watch- Ticker
- SMMT
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 371979717
- Phone
- 305-203-2034
- Business address
- 601 BRICKELL KEY DRIVE, SUITE 1000, MIAMI, FL, 33131
- Former names
- Summit Therapeutics plc, Summit Corp plc
- 4 Derivatives Options or other derivatives
- 4 Option exercise Co-Chief Executive Officer acquired 315,681 shares (option exercise)
- 4 Grant or award Co-Chief Executive Officer acquired 44,052 shares (grant or award)
- 4 Grant or award Co-Chief Executive Officer acquired 3,325,991 shares (grant or award)
- 4 Grant or award Director acquired 44,052 shares (grant or award)
- 4 Grant or award COO and CFO acquired 44,052 shares (grant or award)
- 4 Grant or award Chief Accounting Officer acquired 22,026 shares (grant or award)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Open-market buy Chief Executive Officer bought 110,321 shares at an average $3.73 ($411,094)
- 4 Open-market buy Chief Financial Officer bought 100,000 shares at $3.75 ($375,000)
- 5 Insider Annual Insider Trading Report
- 4 Derivatives Options or other derivatives
Page 3 of 7 · 130 filings